Syndax’s Revuforj® (revumenib) Named to TIME’s Best Inventions of 2026 List
Key Highlights
- ➤Revuforj named to TIME’s Best Inventions of 2026 medical category
- ➤Revuforj FDA-approved for relapsed or refractory acute leukemia patients one year and older
- ➤October 2025 FDA expansion added NPM1-mutated relapsed or refractory AML indication
- ➤November 2024 FDA approval covered KMT2A-translocated relapsed or refractory acute leukemia
- ➤Multiple revumenib trials ongoing or planned across newly diagnosed and combination settings
NEW YORK, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Revuforj(®) (revumenib), the Company’s first-in-class menin inhibitor, has been selected by TIME as one of the “Best Inventions of 2026” in the Medical and Healthcare category.
TIME’s annual list of the Best Inventions features 300 extraordinary inventions changing lives. To compile this year's list, TIME solicited nominations from TIME editors and correspondents around the world, and through an online application process, paying special attention to growing fields—such as healthcare and AI. TIME then evaluated each contender on a number of key factors, including originality, efficacy, ambition, and impact. To view the full list of best inventions in the Medical and Healthcare category, click here. To view the Revuforj brief, click here.
Get started
Create a free account to read the full story.